|
US3655679A
(en)
|
1969-06-25 |
1972-04-11 |
Merck & Co Inc |
Certain aryl pyridine carboxylic acid derivatives
|
|
US3703582A
(en)
|
1970-04-20 |
1972-11-21 |
Merck & Co Inc |
Aryl pyridine carboxylic acids in the treatment of inflammation
|
|
US3894920A
(en)
|
1971-12-21 |
1975-07-15 |
Sagami Chem Res |
Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
|
|
US4016287A
(en)
|
1972-07-17 |
1977-04-05 |
Boehringer Ingelheim Gmbh |
Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
|
|
CA1261335A
(en)
|
1984-08-29 |
1989-09-26 |
Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee |
Ethylenediamine monoamide derivatives
|
|
CN1023479C
(zh)
|
1985-09-27 |
1994-01-12 |
弗·哈夫曼-拉罗切有限公司 |
乙二胺的单酰胺衍生物的制备方法
|
|
TW219933B
(cg-RX-API-DMAC7.html)
|
1990-02-26 |
1994-02-01 |
Lilly Co Eli |
|
|
US5405613A
(en)
|
1991-12-11 |
1995-04-11 |
Creative Nutrition Canada Corp. |
Vitamin/mineral composition
|
|
TW352384B
(en)
|
1992-03-24 |
1999-02-11 |
Hoechst Ag |
Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
|
|
DE4219158A1
(de)
|
1992-06-11 |
1993-12-16 |
Thomae Gmbh Dr K |
Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
|
ES2101421T3
(es)
|
1993-11-02 |
1997-07-01 |
Hoechst Ag |
Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
|
|
EP0650960B1
(de)
|
1993-11-02 |
1997-03-05 |
Hoechst Aktiengesellschaft |
Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
NZ270267A
(en)
|
1993-12-30 |
1997-03-24 |
Hoechst Ag |
3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
|
|
DE4410480A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
DE4410423A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
US5789426A
(en)
|
1995-01-20 |
1998-08-04 |
Cornell Research Foundation, Inc. |
Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
|
|
DE19535571A1
(de)
|
1995-09-14 |
1997-03-20 |
Boehringer Mannheim Gmbh |
Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
|
|
IL135495A
(en)
|
1995-09-28 |
2002-12-01 |
Hoechst Ag |
Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
|
|
JPH09221476A
(ja)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
医薬組成物
|
|
KR20000065090A
(ko)
|
1996-04-30 |
2000-11-06 |
훽스트 악티엔게젤샤프트 |
3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
|
|
DE19620041A1
(de)
|
1996-05-17 |
1998-01-29 |
Merck Patent Gmbh |
Adhäsionsrezeptor-Antagonisten
|
|
DE19650215A1
(de)
|
1996-12-04 |
1998-06-10 |
Hoechst Ag |
3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
EP1024134A4
(en)
|
1997-10-09 |
2003-05-14 |
Ono Pharmaceutical Co |
DERIVATIVES OF AMINOBUTANIC ACID
|
|
DE19746287A1
(de)
|
1997-10-20 |
1999-04-22 |
Hoechst Marion Roussel De Gmbh |
Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
BR9909086A
(pt)
|
1998-03-23 |
2001-09-04 |
Aventis Pharm Prod Inc |
Derivados de piperidinila e n-amidinopiperidinila
|
|
GB9809213D0
(en)
*
|
1998-04-29 |
1998-07-01 |
Glaxo Group Ltd |
Pharmaceutical compositions
|
|
HUP0102206A3
(en)
|
1998-06-11 |
2002-12-28 |
Upjohn Co |
Delavirdine tablet formulation
|
|
US6159379A
(en)
|
1999-05-04 |
2000-12-12 |
Baker Hughes Incorporated |
Organic ammonium salts for the removal of water soluble organics in produced water
|
|
JP2001048786A
(ja)
|
1999-08-05 |
2001-02-20 |
Yamanouchi Pharmaceut Co Ltd |
三環式ヘテロアリール誘導体
|
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
|
PL362687A1
(en)
|
2001-01-12 |
2004-11-02 |
Sun Pharmaceutical Industries Limited |
Spaced drug delivery system
|
|
US6855510B2
(en)
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
|
US6849718B2
(en)
|
2001-03-20 |
2005-02-01 |
Dana Farber Cancer Institute, Inc. |
Muteins of hypoxia inducible factor alpha and methods of use thereof
|
|
EP1379630B1
(en)
|
2001-03-21 |
2012-09-26 |
Isis Innovation Limited |
Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
|
|
SE0101327D0
(sv)
|
2001-04-12 |
2001-04-12 |
Astrazeneca Ab |
New crystalline forms
|
|
US6566088B1
(en)
|
2001-10-04 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Prolyl-4-hydroxylases
|
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
US20030176317A1
(en)
*
|
2001-12-06 |
2003-09-18 |
Volkmar Guenzler-Pukall |
Stabilization of hypoxia inducible factor (HIF) alpha
|
|
CN1668296A
(zh)
|
2002-05-17 |
2005-09-14 |
细胞基因公司 |
使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
|
|
WO2003101431A1
(en)
*
|
2002-06-04 |
2003-12-11 |
J.B. Chemicals & Pharmaceuticals Ltd. |
Pharmaceutical composition for controlled drug delivery system
|
|
RU2005108667A
(ru)
|
2002-08-29 |
2005-08-27 |
Мерк энд Ко., Инк. (US) |
Производные n-биарилметиламиноциклоалканкарбоксамида
|
|
EP1554394B1
(en)
|
2002-10-16 |
2009-12-16 |
Isis Innovation Limited |
Screening methods using a structural model of FIH
|
|
WO2004048383A1
(en)
|
2002-11-21 |
2004-06-10 |
Eli Lilly And Company |
Mixed lineage kinase modulators
|
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
|
US7618940B2
(en)
|
2002-12-06 |
2009-11-17 |
Fibrogen, Inc. |
Fat regulation
|
|
US7183287B2
(en)
|
2003-04-03 |
2007-02-27 |
Pharmacia Corporation |
Substituted pyrimidinones
|
|
WO2005007192A2
(en)
|
2003-06-06 |
2005-01-27 |
Fibrogen, Inc. |
Cytoprotection through the use of hif hydroxylase inhibitors
|
|
US8614204B2
(en)
|
2003-06-06 |
2013-12-24 |
Fibrogen, Inc. |
Enhanced erythropoiesis and iron metabolism
|
|
NZ543448A
(en)
|
2003-06-06 |
2009-02-28 |
Fibrogen Inc |
Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
|
|
GB0314129D0
(en)
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
|
CA2567619A1
(en)
|
2004-05-28 |
2005-12-15 |
Fibrogen, Inc. |
Hif prolyl hydroxylase activity assay
|
|
JP2008500951A
(ja)
|
2004-05-31 |
2008-01-17 |
田辺三菱製薬株式会社 |
二環化合物
|
|
JP2008506702A
(ja)
|
2004-07-14 |
2008-03-06 |
ピーティーシー セラピューティクス，インコーポレーテッド |
Ｃ型肝炎を治療するための方法
|
|
TW200616969A
(en)
|
2004-09-17 |
2006-06-01 |
Tanabe Seiyaku Co |
Imidazole compound
|
|
WO2006084210A2
(en)
|
2005-02-04 |
2006-08-10 |
Regents Of The University Of California, San Diego |
Hif modulating compounds and methods of use thereof
|
|
DE102005019712A1
(de)
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone und ihre Verwendung
|
|
JP5390184B2
(ja)
|
2005-06-06 |
2014-01-15 |
ファイブローゲン、インコーポレーテッド |
貧血の改良された治療方法
|
|
CN101242817B
(zh)
|
2005-06-15 |
2016-08-31 |
菲布罗根公司 |
HIF1α调节剂在治疗癌症中的用途
|
|
WO2007031933A2
(en)
|
2005-09-12 |
2007-03-22 |
Actelion Pharmaceuticals Ltd |
Stable pharmaceutical composition comprising a pyrimidine-sulfamide
|
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
WO2007038571A2
(en)
|
2005-09-26 |
2007-04-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase antagonists
|
|
WO2007047194A2
(en)
|
2005-10-11 |
2007-04-26 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating mitf-related disorders
|
|
ES2446416T3
(es)
|
2005-12-09 |
2014-03-07 |
Amgen, Inc. |
Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos
|
|
EP1971618A2
(en)
|
2006-01-09 |
2008-09-24 |
Btg International Limited |
Modulators of hypoxia inducible factor-1 and related uses
|
|
WO2007082899A1
(en)
|
2006-01-17 |
2007-07-26 |
Vib Vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
|
JP2009523812A
(ja)
|
2006-01-19 |
2009-06-25 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
融合へテロ二環式キナーゼ阻害剤
|
|
JP4801451B2
(ja)
|
2006-01-19 |
2011-10-26 |
株式会社日立ハイテクノロジーズ |
走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
|
|
ITMI20060179A1
(it)
|
2006-02-02 |
2007-08-03 |
Abiogen Pharma Spa |
Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
|
|
WO2007101204A1
(en)
|
2006-02-27 |
2007-09-07 |
Alcon Research, Ltd. |
Method of treating glaucoma
|
|
AR059733A1
(es)
|
2006-03-07 |
2008-04-23 |
Smithkline Beecham Corp |
Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
|
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
|
WO2007136990A2
(en)
|
2006-05-16 |
2007-11-29 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
KR100798730B1
(ko)
*
|
2006-06-12 |
2008-01-29 |
신풍제약주식회사 |
록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
|
|
TWI394747B
(zh)
|
2006-06-23 |
2013-05-01 |
Smithkline Beecham Corp |
脯胺醯基羥化酶抑制劑
|
|
AU2007265460B2
(en)
|
2006-06-26 |
2011-03-03 |
Akebia Therapeutics Inc. |
Prolyl hydroxylase inhibitors and methods of use
|
|
CA2563690C
(en)
|
2006-10-12 |
2014-10-07 |
Pharmascience Inc. |
Pharmaceutical compositions comprising intra- and extra- granular fractions
|
|
IES20070122A2
(en)
|
2006-12-05 |
2008-05-28 |
Michael Hilary Burke |
A process for the preparation of an orally administered unit dose tablet
|
|
TW200845991A
(en)
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: hydroxylase inhibitors
|
|
TW200845994A
(en)
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: prolyl hydroxylase inhibitors
|
|
EP2134326B1
(en)
|
2007-04-17 |
2011-11-16 |
Ratiopharm GmbH |
Pharmaceutical compositions comprising irbesartan
|
|
CA2683758A1
(en)
|
2007-04-18 |
2008-10-30 |
Merck & Co., Inc. |
Novel 1,8-naphthyridine compounds
|
|
EP2155680B1
(en)
|
2007-04-18 |
2013-12-04 |
Amgen, Inc |
Indanone derivatives that inhibit prolyl hydroxylase
|
|
CA2685216C
(en)
|
2007-05-04 |
2014-07-08 |
Amgen Inc. |
Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
|
|
EP2160187B1
(en)
|
2007-05-16 |
2013-05-22 |
Merck Sharp & Dohme Corp. |
Spiroindalones
|
|
AU2008253311A1
(en)
|
2007-05-18 |
2008-11-27 |
Bayer Schering Pharma Aktiengesellshaft |
Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
|
|
US8268794B2
(en)
|
2007-08-06 |
2012-09-18 |
Senju Pharmaceutical Co., Ltd. |
Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor
|
|
TW200908984A
(en)
|
2007-08-07 |
2009-03-01 |
Piramal Life Sciences Ltd |
Pyridyl derivatives, their preparation and use
|
|
KR20100045480A
(ko)
|
2007-08-10 |
2010-05-03 |
크리스탈지노믹스(주) |
피리딘 유도체 및 이들의 사용방법
|
|
WO2009035534A2
(en)
|
2007-09-07 |
2009-03-19 |
The Cleveland Clinic Foundation |
Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
|
|
WO2009039323A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009039321A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009043093A1
(en)
|
2007-10-04 |
2009-04-09 |
Newsouth Innovations Pty Limited |
Hif inhibition
|
|
WO2009049112A1
(en)
|
2007-10-10 |
2009-04-16 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009067790A1
(en)
|
2007-11-26 |
2009-06-04 |
Uti Limited Partnership |
STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
|
|
JP2011508725A
(ja)
|
2007-11-30 |
2011-03-17 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
プロリルヒドロキシラーゼ阻害剤
|
|
WO2009070644A1
(en)
|
2007-11-30 |
2009-06-04 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009073669A1
(en)
|
2007-12-03 |
2009-06-11 |
Fibrogen, Inc. |
Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
|
|
JP2011507894A
(ja)
|
2007-12-19 |
2011-03-10 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
プロリルヒドロキシラーゼ阻害剤
|
|
WO2009086592A1
(en)
|
2008-01-04 |
2009-07-16 |
Garvan Institute Of Medical Research |
Method of increasing metabolism
|
|
US8952160B2
(en)
|
2008-01-11 |
2015-02-10 |
Fibrogen, Inc. |
Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
|
|
KR101208778B1
(ko)
|
2008-03-03 |
2012-12-05 |
노파르티스 아게 |
Ｔｌｒ 활성 조정제로서의 화합물 및 조성물
|
|
KR20110033291A
(ko)
|
2008-07-23 |
2011-03-30 |
에프. 호프만-라 로슈 아게 |
헤테로사이클릭 항바이러스 화합물
|
|
TW201006473A
(en)
*
|
2008-08-13 |
2010-02-16 |
Orient Pharma Co Ltd |
Bi-layer medicine tablet containing Zaleplon
|
|
BRPI0913485A2
(pt)
|
2008-09-15 |
2016-06-07 |
Kasina Laila Innova Pharmaceuticals Private Ltd |
medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.
|
|
HU230877B1
(hu)
*
|
2008-09-30 |
2018-11-29 |
EGIS Gyógyszergyár NyR |
Stabil kombinációs gyógyszerkészítmény
|
|
CN105037323A
(zh)
|
2008-11-14 |
2015-11-11 |
菲布罗根有限公司 |
作为hif羟化酶抑制剂的苯并噻喃衍生物
|
|
US8137666B2
(en)
*
|
2008-11-22 |
2012-03-20 |
Academia Sinica |
Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses
|
|
KR101772963B1
(ko)
|
2009-03-31 |
2017-08-31 |
깃세이 야쿠힌 고교 가부시키가이샤 |
인돌리진 유도체 및 그 의약용도
|
|
WO2010114801A1
(en)
|
2009-03-31 |
2010-10-07 |
Ligand Pharmaceuticals Inc. |
Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
|
|
AR077417A1
(es)
|
2009-07-17 |
2011-08-24 |
Japan Tobacco Inc |
Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa o agente inductor de la produccion de eritropoyetina
|
|
PH12012500788A1
(en)
|
2009-11-06 |
2016-07-27 |
Aerpio Therapeutics Inc |
Compositions and methods for treating colitis
|
|
CN103429239A
(zh)
|
2011-01-13 |
2013-12-04 |
菲布罗根有限公司 |
增加网织红细胞血红蛋白含量的方法
|
|
US8865748B2
(en)
|
2011-06-06 |
2014-10-21 |
Akebia Therapeutics Inc. |
Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
|
|
NO2686520T3
(cg-RX-API-DMAC7.html)
|
2011-06-06 |
2018-03-17 |
|
|
|
WO2012174256A2
(en)
|
2011-06-17 |
2012-12-20 |
The Regents Of The University Of Michigan |
Dna methylation profiles in cancer
|
|
JP6099644B2
(ja)
|
2011-07-22 |
2017-03-22 |
ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド |
プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
|
|
CN105492011A
(zh)
|
2013-04-08 |
2016-04-13 |
丹尼斯·M·布朗 |
不理想给药化学化合物的治疗增效
|
|
MY204336A
(en)
|
2013-06-13 |
2024-08-23 |
Akebia Therapeutics Inc |
Compositions and methods for treating anemia
|
|
JP2016529257A
(ja)
|
2013-08-16 |
2016-09-23 |
オハイオ ステート イノベーション ファウンデーション |
Ｄｎａメチル化を調節する組成物及び方法
|
|
CN114890943A
(zh)
|
2013-11-15 |
2022-08-12 |
阿克比治疗有限公司 |
{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途
|
|
JP2017503835A
(ja)
|
2014-01-23 |
2017-02-02 |
アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． |
眼球疾患治療のための組成物及び方法
|
|
AU2016209126A1
(en)
|
2015-01-23 |
2017-08-10 |
Akebia Therapeutics, Inc. |
Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
|
|
AU2016235534A1
(en)
|
2015-03-20 |
2017-10-12 |
Akebia Therapeutics, Inc. |
Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
|
|
UA123308C2
(uk)
|
2015-04-01 |
2021-03-17 |
Екебіа Терапьютікс, Інк. |
Композиції і способи для лікування анемії
|
|
WO2019028150A1
(en)
|
2017-08-01 |
2019-02-07 |
Akebia Therapeutics, Inc. |
COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
|
|
AU2019355097A1
(en)
|
2018-10-03 |
2021-05-27 |
Akebia Therapeutics, Inc. |
Benzimidazole derivative for use in the treatment of inflammatory disorders
|
|
US11524939B2
(en)
*
|
2019-11-13 |
2022-12-13 |
Akebia Therapeutics, Inc. |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
|